Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 85.23 USD 1.46%
Market Cap: 9B USD
Have any thoughts about
Intra-Cellular Therapies Inc?
Write Note

Intra-Cellular Therapies Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intra-Cellular Therapies Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Cash from Financing Activities
$564.9m
CAGR 3-Years
327%
CAGR 5-Years
290%
CAGR 10-Years
17%
Johnson & Johnson
NYSE:JNJ
Cash from Financing Activities
-$6.4B
CAGR 3-Years
27%
CAGR 5-Years
21%
CAGR 10-Years
5%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Financing Activities
$7.7B
CAGR 3-Years
N/A
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Cash from Financing Activities
-$5.7B
CAGR 3-Years
34%
CAGR 5-Years
14%
CAGR 10-Years
8%
Merck & Co Inc
NYSE:MRK
Cash from Financing Activities
-$6.3B
CAGR 3-Years
-72%
CAGR 5-Years
13%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Cash from Financing Activities
$5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Intra-Cellular Therapies Inc
Glance View

Market Cap
9B USD
Industry
Pharmaceuticals
Economic Moat
Narrow

Intra-Cellular Therapies Inc., founded in 2002, finds itself at the intersection of scientific innovation and commercial success. This biopharmaceutical company is built around the vision of translating ground-breaking discoveries in neuroscience into important medications for serious neuropsychiatric and neurological disorders. The firm’s flagship product, CAPLYTA (lumateperone), exemplifies its dedication to comprehensive central nervous system solutions. Approved by the FDA for the treatment of schizophrenia in adults, and later approved for bipolar depression, CAPLYTA positions Intra-Cellular Therapies within a competitive landscape of mental health treatments. It is through pharmaceutical sales of CAPLYTA that Intra-Cellular Therapies generates revenue, capitalizing on extensive research to carve out a niche in a market with significant medical needs. Operating predominantly in the United States, Intra-Cellular Therapies harnesses its proprietary technologies, including PDE1 inhibition and other novel mechanisms of action, to pioneer treatments aimed at improving patients' quality of life. The company invests heavily in research and development, fueled by its robust clinical pipeline that constantly explores new therapeutic opportunities. Their approach involves not just the development of medications but also extensive engagement with healthcare providers and thought leaders to better understand and serve the patient community. This strategy underscores a business model where innovation directly translates to market viability, as the company embarks on long-term growth through the expansion of indications for its existing drugs and exploration of new compounds.

ITCI Intrinsic Value
64.7 USD
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Intra-Cellular Therapies Inc's Cash from Financing Activities?
Cash from Financing Activities
564.9m USD

Based on the financial report for Sep 30, 2024, Intra-Cellular Therapies Inc's Cash from Financing Activities amounts to 564.9m USD.

What is Intra-Cellular Therapies Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
17%

Over the last year, the Cash from Financing Activities growth was 3 223%. The average annual Cash from Financing Activities growth rates for Intra-Cellular Therapies Inc have been 327% over the past three years , 290% over the past five years , and 17% over the past ten years .

Back to Top